AtheroGenics' ARISE Trial Results Published In The Lancet

"The ARISE try-out hold bestow us next to trace that succinobucol may be a up-and-coming nothing similar to abstraction therapy, base by process of clinical shift delimited by a digit of prespecified diabetes and cardiovascular endpoints," stated Dr. Jean-Claude Tardif, Co-Primary Investigator of the ARISE be trained, controller of the Montreal Heart Institute Research Centre and professor of prescription at the Montreal Heart Institute and the Université de Montréal. "Although ARISE miss its introductory endpoint of reducing a composite of cardiovascular endpoints, we assume the study notes unambiguously symbolize that succinobucol should be further investigate to rear all-encompassing up and something like its cunning to mortgage glucose steadfastness in patients with diabetes and to impulse smaller cardiovascular actions in patients with heart syndrome." Interested gathering will be competent to access this week's edition of The Lancet by pop in their website at Once you access the website, click on "This Week's Issue," and consequently click on "articles." About AtheroGenics AtheroGenics be decided on the finding, upgrading and commercialization of new-fangled drugs in desire of the usage of incurable inflammatory disease, plus diabetes and coronary heart disease (atherosclerosis). The Company's face antioxidant and anti-inflammatory pills participator, AGI-1067, is person studied in a Phase III clinical trial certain by means of ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), for the treatment of diabetes. In rider, the Company has other clinical and preclinical anti-inflammatory compound, including AGI-1096, an oral agent for the disincentive of organ transplant snub. For more news about AtheroGenics, make delighted visit Disclosure Regarding Forward-Looking Statements Statements contained here grasp unchain that tell to events or development that we predict or anticipate will transpire in the close to be deem to be forward-looking statement, and can be identified by lines such as "believes," "intends," "expects" and parallel expressions. AtheroGenics caution investor not to plonk undue notion on the forward-looking statements contained in this release. These statements are thesis to in no doubt factor, speculate and uncertainties that may cause actual grades, events and exploitable to be evidence of a variation materially from those referred to in such statements. For illustration, supplementary information relating to the sanctuary, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. The U.S. Food and Drug Administration may well not allow us to conduct further study of the efficacy of AGI-1067 for alike or new endpoints, and, to the size conceded, additional clinical trial sweat may help yourself to a switch extent of juncture to out-and-out or necessitate significant additional possessions to complete. We cannot ensure that AGI-1067 will ever be approved or be proven safe and sound and rationalized for using up in human. These and other risks are deliberate in AtheroGenics' Securities and Exchange Commission filings, including, but not durable to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year terminated December 31, 2007 and are clearly incorporated by excerpt into this press release. We engage in no discouragement to publicly update any forward-looking affidavit, whether thus of new information, future events, or otherwise.

I made a choice of online-drugstore. This is Qpills.net. I buy carb blocker on Qpills.net